To compare the efficiency between surgery and radiotherapy after SHR-1316 (Adebrelimab)and platinum-containing doublet induction therapy for limited-stage small cell lung cancer
after signing informed consent;
Aged 18-70;
Histologically or cytologically confirmed SCLC, imaging examination and other confirmed limited-stage small cell lung cancer, and without previous treatment;
For clinical stage IIB-III, all patients should have clear lymph node pathology by EBUS to exclud occult lymph node metastasis.
Received any systemic anticancer therapy, including surgery, local radiotherapy, cytotoxic drug therapy, targeted drug therapy, and experimental therapy;
Patients with other malignancies within five years prior to the start of the trial;
Combined with unstable systemic diseases, such as uncontrolled hypertension, severe arrhythmia, etc;
With active, known or suspected autoimmune disease, or autoimmune paraneoplastic syndrome requiring systemic therapy;
Map coordinates are unavailable for these locations. Locations are shown below instead.
ChinaShanghai Pulmonary Hospital, Shanghai, China
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborator